Connect Biopharma Holdings Limited (CNTB) — Financial statements
Income statement, balance sheet, and cash flow for Connect Biopharma Holdings Limited — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.06↓99.8% | 26 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.06↓99.8% | 26 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 38↑29.2% | 29↓44.8% | 53↓45.1% | 97↑20.0% | 80 | |
| General & Administrative Expenses | 20↑5.8% | 19↑19.8% | 16↓22.8% | 21↑9.4% | 19 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 20↑5.8% | 19↑19.8% | 16↓22.8% | 21↑9.4% | 19 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 2↑234.0% | -1 | |
| Operating Expenses | 58↑19.9% | 48↓29.8% | 69↓42.1% | 119↑21.6% | 98 | |
| Total Costs & Expenses | 58↑19.9% | 48↓29.8% | 69↓42.1% | 119↑21.6% | 98 | |
| Operating Results | ||||||
| Operating Income | -58↓158.7% | -22↑67.5% | -69↑42.1% | -119↓21.6% | -98 | |
| Depreciation & Amortization | 0.70↑6.7% | 0.66↓8.3% | 0.72↓30.2% | 1↑62.6% | 0.63 | |
| EBITDA | -57↓163.3% | -22↑68.1% | -68↑41.5% | -117↑42.0% | -201 | |
| EBIT | -58↓158.7% | -22↑67.5% | -69↑41.4% | -118↑41.7% | -202 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓49.1% | 4↑85551.1% | 0.01↓99.7% | 2↑1601.1% | 0.09 | |
| Interest Income | 2↓49.1% | 4↑85551.1% | 0.01↓99.7% | 2↑1502.3% | 0.10 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.02↑204.4% | 0.01 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -2↓101.5% | 104 | |
| Other Income / Expenses | 3↓60.4% | 7↓0.3% | 7↑364.2% | 2↑101.5% | -104 | |
| Income Before Tax | -55↓258.9% | -15↑75.1% | -62↑47.4% | -118↑41.7% | -202 | |
| Income Tax Expense | 0.20↓11.7% | 0.22↑85.8% | 0.12↓59.7% | 0.30↑12.0% | 0.27 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -55↓255.0% | -16↑74.8% | -62↑47.4% | -118↑41.6% | -202 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -55↓255.0% | -16↑74.8% | -62↑47.4% | -118↑41.6% | -202 | |
| Bottom-Line Net Income | -55↓255.0% | -16↑74.8% | -62↑47.4% | -118↑41.6% | -202 | |
| EPS (Basic) | -1.00↓257.1% | -0.28↑74.1% | -1.08↑92.6% | -14.50↑42.0% | -25.00 | |
| EPS (Diluted) | -1.00↓257.1% | -0.28↑74.1% | -1.08↑92.6% | -14.50↑42.0% | -25.00 | |
| Weighted Average Shares | 56↑0.8% | 55↑0.3% | 55↑0.0% | 55↑5.3% | 52 | |
| Weighted Average Diluted Shares | 56↑0.8% | 55↑0.3% | 55↑0.0% | 55↑5.3% | 52 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.